Biocon inches up as its arm receives tentative approval from USFDA for Sitagliptin Tablets USP
Biocon is currently trading at Rs. 359.50, up by 0.90 points or 0.25% from its previous closing of Rs. 358.60 on the BSE.
The scrip opened at Rs. 360.90 and has touched a high and low of Rs. 362.85 and Rs. 356.70 respectively. So far 34579 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 405.90 on 18-Jul-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 363.50 and Rs. 354.85 respectively. The current market cap of the company is Rs. 48117.32 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.86% and 16.68% respectively.
Biocon’s wholly owned subsidiary -- Biocon Pharma has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Sitagliptin Tablets USP, in 25 mg, 50 mg and 100 mg strengths. Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The approval will further strengthen company’s portfolio of vertically integrated drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
